Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.
Antitumor effect and toxicity of single-drug treatment with per oral VP-16-213 (etoposide) were evaluated in a phase II trial which included 22 patients with recurrence or progression of ovarian carcinoma. Two of these patients were evaluable only for toxicity. All patients had previously been treated with a combination chemotherapy involving at least three different drugs. The median age was 59 years (range 21-76). VP-16-213 was administered orally at a daily dose of 200 mg/m2 for 4 consecutive days every third week with systematic dose escalation. Fourteen patients were treated to grade 3-4 hematologic toxicity (WHO) and 8 to grade 0-2. Eleven experienced nausea and vomiting and 4 partial alopecia. One patient achieved a CR and another a PR with a duration of 3 months and 5 + months, respectively.
Hansen
F
F
Department of Oncology, Herlev University Hospital, Denmark.
Malthe
I
I
Krog
H
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D005047:Etoposide